SAT0391 REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE – POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK
Authors: Brigitte Michelsen, Cecilie Heegaard Brahe, Lennart T.H. Jacobsson, Michael Nissen, Manuel Pombo-Suarez, Heřman Mann, Ziga Rotar, Joe Sexton, Maria Jose Santos, Dan Nordström, Catalin Codreanu, Björn Gudbjornsson, Sema Yilmaz, Florenzo Iannone, Ulf Lindström, Anne Gitte Loft, Burkhard Moeller, Carlos Sánchez-Piedra, Karel Pavelka, Matija Tomsic, Eirik Kristianslund, Helena Santos, Anna-Mari Hokkanen, Ruxandra Ionescu, Thorvardur Jon Love, Yavuz Pehlivan, Marco Sebastiani, Gareth T. Jones, Irene van der Horst-Bruinsma, Lise Hyldstrup, Niels Steen Krogh, Merete L. Hetland, Mikkel Östergaard
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> There is a lack of data on exposure, treatment outcomes and retention rates of secukinumab in patients with psoriatic arthritis (PsA) treated in routine care. <h3>Objectives</h3> Primary objective: To assess the proportion of PsA patients in remission after 6 months of secukinumab treatment across Europe. Secondary objectives: To compare baseline clinical and demographic characteristics, 6-month crude and LUNDEX adjusted remission rates, 6-month retention rates and median time to secukinumab withdrawal (due to loss of efficacy/adverse events) between bDMARD naïve and non-naïve patients as well as across the participating European registries. <h3>Methods</h3> PsA patients starting secukinumab in routine care and followed for at least 6 months were included from 12 European registries within the European Spondyloarthritis Research Collaboration (EuroSpA). Independent t-test, Mann-Whitney U test, ANOVA, Kruskal-Wallis and Chi-square test were used for group comparisons as appropriate, and Kaplan-Meier plots with log rank test for comparison of secukinumab drug survival. <h3>Results</h3> A total of 1549 PsA patients starting secukinumab were included (Table). 6-month remission and retention rates were significantly different between the registries (Table). Biologic DMARD (bDMARD) naïve compared with non-naïve patients had significantly higher 6-month remission rates and a trend towards better 6-month retention rates (Table, Figure 1a-b). <h3>Conclusion</h3> This study of &gt;1500 patients in 12 European countries provides real-world data on the effectiveness of secukinumab in patients with PsA, adding evidence to existing RCTs. A majority of the patients had long disease duration and was previous bDMARD users. DAS28CRP, SDAI and DAPSA28 remission at 6 months were achieved by 35%, 12% and 12%, respectively. The overall retention rate was 86%, with significant differences across the registries. bDMARD naïve compared with non-naïve patients had significantly better 6-month remission rates and a trend towards better secukinumab retention rates. <h3>Acknowledgement</h3> Novartis Pharma AG and IQVIA for supporting the EuroSpA collaboration <h3>Disclosure of Interests</h3> Brigitte Michelsen Grant/research support from: Unrestricted grant: Novartis, Consultant for: Novartis, UCB, Cecilie Heegaard Brahe Grant/research support from: Unrestricted grant: Novartis, Lennart T.H. Jacobsson Consultant for: LJ has received lecture and consulting fees from Pfizer, Abbvie, Novartis, Eli-Lily and Janssen, Michael Nissen Consultant for: AbbVie, Lilly, Novartis, and Pfizer, Manuel Pombo-Suarez: None declared, Heřman Mann Consultant for: Pfizer, Eli Lilly, Sanofi, Speakers bureau: AbbVie, Roche, Pfizer, MSD, Eli Lilly, Sanofi, Ziga Rotar: None declared, Joe Sexton: None declared, Maria Jose Santos: None declared, Dan Nordström Grant/research support from: MSD, Pfizer, Consultant for: AbbVie, BMS, MSD, Novartis, Roche, Pfizer, UCB, Speakers bureau: Novartis, UCB, Catalin Codreanu: None declared, Björn Gudbjornsson: None declared, Sema Yilmaz: None declared, Florenzo Iannone Consultant for: F Iannone has received consultancy fees and/or speaker honoraria from Pfizer, AbbVie, MSD, BMS, Novartis, Lilly, UCB outside this work, Speakers bureau: F Iannone has received consultancy fees and/or speaker honoraria from Pfizer, AbbVie, MSD, BMS, Novartis, Lilly, UCB outside this work, Ulf Lindström: None declared, Anne Gitte Loft: None declared, Burkhard Moeller Consultant for: Swissmedic Human Medicines Expert Committee Member (regulatory agency), Carlos Sánchez-Piedra: None declared, Karel Pavelka: None declared, Matija Tomsic: None declared, Eirik kristianslund: None declared, Helena Santos: None declared, Anna-Mari Hokkanen: None declared, Ruxandra Ionescu: None declared, Thorvardur Jon Love Consultant for: Received reimbursment from Celgene for speaking about guidelines for the treatment of psoriatic arthritis, Yavuz Pehlivan: None declared, Marco Sebastiani: None declared, Gareth T. Jones Grant/research support from: Have received research grants (not current) from Abbvie and Pfizer. Have received research grants (not current) from the British Society for Rheumatology, who received the funds from Abbive, Pfizer and UCB. Have received research grant (current) from the British Society for Rheumatology, who received the funds from Celgene., Irene van der Horst-Bruinsma Grant/research support from: MSD, Pfizer, AbbVie, Consultant for: Abbvie, UCB, MSD, Novartis, Speakers bureau: BMS, AbbVie, Pfizer, MSD, Lise Hyldstrup: None declared, Niels Steen Krogh: None declared, Merete L. Hetland Grant/research support from: BMS, MSD, AbbVie, Roche, Novartis, Biogen, Pfizer, Consultant for: Eli Lilly, Speakers bureau: Orion Pharma, Biogen, Pfizer, CellTrion, Merck, Samsung Bioepis, Mikkel Östergaard Grant/research support from: Abbvie, Celgene, Centocor, Merck, Novartis, Consultant for: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, Speakers bureau: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB